These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16338865)

  • 1. Does smoking change the efficacy of combination therapy with vitamin E and colchicines in patients with early-stage Peyronie's disease?
    Cakan M; Demirel F; Aldemir M; Altug U
    Arch Androl; 2006; 52(1):21-7. PubMed ID: 16338865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Conservative treatment of Peyronie's disease: colchicine vs. colchicine plus vitamin E].
    Cortés-González JR; Glina S
    Actas Urol Esp; 2010 May; 34(5):444-9. PubMed ID: 20470717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peyronie's disease in diabetic patients being screened for erectile dysfunction.
    El-Sakka AI; Tayeb KA
    J Urol; 2005 Sep; 174(3):1026-30. PubMed ID: 16094040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome analysis for conservative management of Peyronie's disease.
    Hashimoto K; Hisasue S; Kato R; Kobayashi K; Shimizu T; Tsukamoto T
    Int J Urol; 2006 Mar; 13(3):244-7. PubMed ID: 16643617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease.
    Prieto Castro RM; Leva Vallejo ME; Regueiro Lopez JC; Anglada Curado FJ; Alvarez Kindelan J; Requena Tapia MJ
    BJU Int; 2003 Apr; 91(6):522-4. PubMed ID: 12656907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracorporeal shockwave therapy for Peyronie's disease: an alternative treatment?
    Poulakis V; Skriapas K; de Vries R; Dillenburg W; Ferakis N; Witzsch U; Melekos M; Becht E
    Asian J Androl; 2006 May; 8(3):361-6. PubMed ID: 16625288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Peyronie's disease among patients with erectile dysfunction.
    El-Sakka AI
    Eur Urol; 2006 Mar; 49(3):564-9. PubMed ID: 16386353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease.
    Novak TE; Bryan W; Templeton L; Sikka S; Hellstrom WJ
    J La State Med Soc; 2001 Jul; 153(7):358-63. PubMed ID: 11519219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease.
    Cavallini G; Modenini F; Vitali G
    Urology; 2007 May; 69(5):950-4. PubMed ID: 17482941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach.
    Hauck EW; Hauptmann A; Bschleipfer T; Schmelz HU; Altinkilic BM; Weidner W
    J Urol; 2004 Jan; 171(1):296-9. PubMed ID: 14665898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral therapy for Peyronie's disease.
    Mynderse LA; Monga M
    Int J Impot Res; 2002 Oct; 14(5):340-4. PubMed ID: 12454684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study.
    Riedl CR; Sternig P; Gallé G; Langmann F; Vcelar B; Vorauer K; Wagner A; Katinger H; Pflüger H
    Eur Urol; 2005 Oct; 48(4):656-61. PubMed ID: 15982798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of hyperthermia in the treatment of Peyronie's disease: a preliminary study.
    Perugia G; Liberti M; Vicini P; Colistro F; Gentile V
    Int J Hyperthermia; 2005 Jun; 21(4):367-74. PubMed ID: 16019862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's disease: a randomized and prospective study.
    Inal T; Tokatli Z; Akand M; Ozdiler E; Yaman O
    Urology; 2006 May; 67(5):1038-42. PubMed ID: 16581113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease.
    Stancik I; Schäfer R; Andrukhova O; Oeser R; Plas E; Pflüger H
    Urology; 2009 Sep; 74(3):566-70. PubMed ID: 19604562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of propoleum dosage in Peyronie's disease].
    Lemourt Oliva M; Rodríguez Barroso A; Bordonado Ramírez R; González Oramas E; Molina Castillo F
    Arch Esp Urol; 2003 Sep; 56(7):814-9. PubMed ID: 14595886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The most commonly altered type of Peyronie's disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side.
    Akman T; Sanli O; Uluocak N; Akbulut F; Nane I; Demir S; Kadioglu A
    Andrologia; 2011 Feb; 43(1):28-33. PubMed ID: 21219379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of current nonsurgical management of Peyronie's disease.
    Levine LA
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S113-20. PubMed ID: 14551587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease?].
    Demey A; Chevallier D; Bondil P; Toubol J; Amiel J
    Prog Urol; 2006 Feb; 16(1):52-7. PubMed ID: 16526540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.